Abstract:Introduction: Cardiovascular diseases have been the leading causes of death all over the world for decades. Vascular smooth muscle cells (VSMCs) form a major section of a blood vessel, conferring structural and physiological support to withstand any change under physiological or pathological conditions. VSMC phenotypic modulation from a contractile phenotype to a synthetic state is pivotal for the development of several vascular diseases such as neointima formation after angioplasty and atherosclerosis. Decreased expression of VSMC differentiation markers including SM ɑ-actin (Acta2), SM-myosin heavy chain (Myh11) and SM22 alpha (Tagln) indicates VSMC phenotypic switching, which is accompanied by increasing VSMC proliferation, migration and synthesis of metalloproteinase[1]. However, the molecular mechanisms that underlie VSMC phenotypic switching remain largely unknown. SMYD2, a SET and MYND domain-containing protein, belongs to the SMYD family of protein lysine methyltransferases. Structurally, SET domain regulates lysine methylation of target proteins (as involved in transcription, cell differentiation and cell proliferation), while zinc finger motif MYND domain may interact with proline rich regions and facilitate protein-protein interaction. SMYD2 was originally reported to methylate histone 3 at lysine 4 (H3K4) and lysine 36 (H3K36) and H4 at lysine 20 (H4K20), and plays an essential role in HIV-1 latency and cardiac development [2-3]. Some studies found that SMYD2 can also methylate non-histone proteins such as p53, Hsp90, and Rb and regulate their functions [4-6]. Interestingly, SMYD2 has recently been implicated in human patients with abdominal aortic aneurysm in GWAS screening [7]. The aim of this study is to investigate the role of SMYD2 in the control of VSMC phenotypic switching and neointima formation. Methods: We used Western blotting and PCR to assess SMYD2 expression and VSMC marker gene expression in VSMC phenotypic change in vitro and murine carotid ligation injury model in vivo. In the ligation injury model, right common carotid artery (CCA) was ligated and harvested after 7, 14, and 28 days. SMYD2smc-/- (SMYD2 conditional knockout in VSMCs) mice and SMYD2flox/flox (SMYD2 flox control) mice were subjected to ligation model and CCA was obtained for histological evaluation after7 days, 14 days and 28days. Primary VSMCs were isolated from SMYD2smc-/- mice and SMYD2flox/flox mice and then VSMC marker gene expression was examined by Western blotting and PCR. Furthermore, we also checked expression of SMYD2 in murine atherosclerosis which is closely related to VSMC phenotypic change. Results: The expression of SMYD2 significantly decreased in response to platelet-derived growth factor BB (PDGF-BB) in the serum-starved VSMCs. In the in vivo model, we found that SMYD2 expression was also reduced in the injured versus sham-operated carotid arteries. In comparison with normal healthy arteries, atherosclerotic arteries have a substantially decreased SMYD2 expression in mouse vascular tissues. Moreover, SMYD2 ablation in VSMCs significantly exacerbated ligation injury-induced neointima formation in mice and drastically inhibited VSMC marker gene expression. Conclusion: Our findings demonstrated that SMYD2 down-regulation in VSMCs promotes VSMC phenotypic changing and neointima formation after injury, suggesting that SMYD2 may function as a novel inhibitor of vascular remodeling associated with physical injury and atherosclerotic disease. Disclosure: Nothing to disclose

SUV39H1 mediated regulation of KLF4 and KDM4A coordinate smooth muscle cell phenotypic plasticity

Inhibition of Polycomb Repressor Complex 2 Ameliorates Neointimal Hyperplasia by Suppressing Trimethylation of H3K27 in Vascular Smooth Muscle Cells.

Methyltransferase Like 3-Mediated N6-methylatidin Methylation Inhibits Vascular Smooth Muscle Cells Phenotype Switching Via Promoting Phosphatidylinositol 3-Kinase Mrna Decay.

Abstract 3142: Pik3c3 Safeguards Smooth Muscle Identity by Promoting Lysosome-mediated Yap1 Degradation

Epigenetic Regulation of Vascular Smooth Muscle Cells by Histone H3 Lysine 9 Dimethylation Attenuates Target Gene-Induction by Inflammatory Signaling

The lysine methyltransferase SMYD2 facilitates neointimal hyperplasia by regulating the HDAC3–SRF axis

Influence of DNA Methylation on Vascular Smooth Muscle Cell Phenotypic Switching

Set and MYND Domain-containing Protein 2 (SMYD2) is a Critical Regulator for Vascular Smooth Muscle Cell Phenotypic Switching and Neointima Formation

Role of the Lysine-Specific Demethylase 1 in the Proinflammatory Phenotype of Vascular Smooth Muscle Cells of Diabetic Mice

Histone Variant H2A.Z is Required for the Maintenance of Smooth Muscle Cell Identity As Revealed by Single-Cell Transcriptomics

H3K4 Methyltransferase Smyd3 Mediates Vascular Smooth Muscle Cell Proliferation, Migration, and Neointima Formation

Integrative analysis of the lncRNA-miRNA-mRNA interactions in smooth muscle cell phenotypic transitions

Epigenetic regulation of vascular smooth muscle cell phenotypic switch and neointimal formation by PRMT5

SMYD2 regulates vascular smooth muscle cell phenotypic switching and intimal hyperplasia via interaction with myocardin

Abstract 433: HDAC7 is Essential for Stem Cell Differentiation into Smooth Muscle Cells

Dynamic changes in chromatin accessibility are associated with the atherogenic transitioning of vascular smooth muscle cells

Sp1-Dependent Activation of Hdac7 is Required for Platelet-Derived Growth Factor-Bb-Induced Smooth Muscle Cell Differentiation from Stem Cells

Splicing of Histone Deacetylase 7 Modulates Smooth Muscle Cell Proliferation and Neointima Formation Through Nuclear Β-Catenin Translocation.

Abstract 14743: Intracellular Adenosine Suppresses Vsmc Phenotypic Switch Through Klf4 Gene Methylation

Matrix Stiffness Determines the Phenotype of Vascular Smooth Muscle Cell in Vitro and in Vivo: Role of DNA Methyltransferase 1

Abstract 212: MicroRNA-663 is a Novel Regulator of Human Vascular Smooth Muscle Cell Phenotypic Switch in vitro and Neointimal Formation in vivo